Trials / NCT07311863
UGX202 Injection in Patients With Advanced Retinitis Pigmentosa
Not yet recruiting Early Phase 1 Gene therapy
- Sponsor
- Suzhou UgeneX Therapeutics Co., Ltd.
- Treatment
- UGX202 injection
- Gene
- Not stated
- Conditions
- Retinitis Pigmentosa (RP)
- Ages
- 18 Years to no upper limit
- Enrollment
- 6 participants
- Started
- 2026-01
- Main results expected
- 2027-03
- Results posted
- Not yet
- Record last updated
- 2025-12-31
What the study is testing
The primary objective of this clinical trial is to evaluate the safety and tolerability of a single intravitreal injection of the gene therapy drug UGX202 in patients with advanced RP. The secondary objective is, to assess the preliminary efficacy of a single intravitreal injection of the gene therapy drug UGX202 in treating patients with advanced RP.
Where it runs
China (1)
- Eye & ENT Hospital of Fudan University, Shanghai, Shanghai Municipality